<DOC>
	<DOCNO>NCT00014612</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell may less invasive treatment cause few side effect complete axillary lymph node dissection . It yet know treatment effective invasive breast cancer . PURPOSE : Randomized phase III trial compare effectiveness complete axillary lymph node dissection axillary radiation therapy treat woman invasive breast cancer .</brief_summary>
	<brief_title>Comparison Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy Treating Women With Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare regional control axilla obtain complete axillary lymph node dissection v axillary radiotherapy sentinel lymph node-positive woman operable invasive breast cancer . - Determine whether local regional axillary control obtain without axillary lymph node dissection sentinel lymph node-negative woman . - Compare axillary 5-year recurrence-free survival patient treat regimen . - Compare morbidity patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center type breast surgery ( conservation v total mastectomy ) . Patients randomize 1 2 treatment arm . Patients give injection tracer undergo lymphoscintigraphy 2-3 hour later identify sentinel lymph node . Within 24 hour lymphoscintigraphy , patient undergo wide local excision tumor mastectomy sentinel node remove . If sentinel node find metastasis find nonsentinel node , patient undergo complete axillary lymph node dissection ( ALND ) regardless randomization . Sentinel node-negative patient receive treatment . Sentinel node-positive patient continue treatment accord randomization . - Arm I : Within 8 week surgery , patient undergo complete ALND . - Arm II : Within 8 week surgery , patient undergo axillary lymph node radiotherapy daily 5 day week 5 week . Patients arm I may receive postoperative axillary irradiation 4 node positive 1 axillary level involve . Quality life assess baseline 1 , 2 , 3 , 5 year . Patients follow annually 5 year . PROJECTED ACCRUAL : A total 3,485 patient ( 1,394 sentinel node-positive 2,091 sentinel node-negative ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically `` triple diagnosis '' ( palpation , mammogram ultrasound , cytology ) confirm operable invasive breast cancer T02 , N0 Diagnosis excisional tumorectomy allow Clinically occult invasive disease must histologically confirm Only 1 tumor 1 breast Tumor 5 50 mm large diameter , within 1 quadrant mammogram , ultrasound MRI Multifocal ( i.e. , within one quadrant share histological characteristic ) allow Multicentric ( i.e. , different quadrant ) breast cancer allow Clinically negative axillary lymph nod No metastatic disease No previous treatment primary breast tumor neoadjuvant hormonal systemic treatment Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Any age Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Fit undergo sentinel node biopsy , axillary clearance , breast surgery , and/or axillary radiotherapy No psychological , familial , sociological , geographical condition would preclude study compliance No prior malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy axilla Surgery : No prior surgery axilla Other : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>